Malaria parasitemia enhances replication of human immunodeficiency virus. Antiretroviral drugs that possess antiplasmodial activity may reverse such an effect. Activity of the antiretroviral drugs lamivudine (L), zidovudine (Z), nevirapine (N), and stavudine (S) against Plasmodium berghei inoculated into 70 adult albino mice was investigated. Eight groups of five animals each were treated with different drugs as either curative or prophylactic regimens. These regimens were also given to four groups as L/Z/N or L/S/N. Z therapy alone and L/Z/N eliminated malaria parasites as follows: curative and prophylactic Z groups, mean ± SEM = 62,132.87 ± 22,816.1 parasites/μL and 62,474.85 ± 14,639.1 parasites/μL, respectively on day 4 and 0 parasites/μL on day 26; curative L/Z/N group, 31,583.53 ± 6,361.67 parasites/μL, and 0 parasites/μL (days 4 and 18, respectively); prophylactic L/Z/N group, 41,138.1 ± 3,528.03 parasites/μL, and 0 parasites/μL (days 4, and 20 respectively). Peters four-day suppressive values were 67-82.2%. Zidovudine or L/Z/N therapy may modify the epidemiology of malaria and therefore the pandemic of human immunodeficiency virus infection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541725PMC
http://dx.doi.org/10.4269/ajtmh.2012.11-0209DOI Listing

Publication Analysis

Top Keywords

antiretroviral drugs
12
plasmodium berghei
8
human immunodeficiency
8
immunodeficiency virus
8
curative prophylactic
8
parasites/μl day
8
l/z/n group
8
parasites/μl parasites/μl
8
parasites/μl days
8
parasites/μl
7

Similar Publications

The clinical management of people with multidrug-resistant (MDR) human immunodeficiency virus (HIV) remains challenging despite continued development of antiretroviral agents. A 58-year-old male individual with MDR HIV and Kaposi sarcoma (KS) was treated with a new antiretroviral regimen consisting of anti-CD4 domain 1 antibody UB-421 and capsid inhibitor lenacapavir. The individual experienced delayed but sustained suppression of plasma viremia and a substantial increase in the CD4 T cell count.

View Article and Find Full Text PDF

Effect of in vitro exposure of first-line antiretrovirals on healthy human spermatozoa on kinematics and motility.

Int Urol Nephrol

January 2025

Department of Urology, Faculty of Health Sciences, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa.

Purpose: Contemporary antiretroviral (ARV) medications are used by millions of men for HIV treatment worldwide. Limited data exist on their direct effect on sperm motility. This pilot study hypothesizes that in vitro exposure to ARVs will reduce sperm kinematic and motility parameter values.

View Article and Find Full Text PDF

Introduction: Antiretroviral treatment (ART) has significantly enhanced health outcomes for people living with HIV (PLWH). With the evolution of treatment options, there is an increasing interest in the development of long-acting injectable formulations of antiretroviral drugs. These formulations present a promising alternative to oral ART.

View Article and Find Full Text PDF

Deciphering Saquinavir-Bovine Serum Albumin Interactions: Spectroscopic and Computational Insights.

J Mol Recognit

January 2025

Biopolymer Modeling and Protein Chemistry Laboratory, Centre for Advanced Studies in Crystallography and Biophysics, University of Madras, Chennai, India.

Bovine serum albumin (BSA) plays a crucial role as a carrier protein in plasma, binding various ligands, including drugs. Understanding the interaction between BSA and saquinavir, an antiretroviral drug, is essential for predicting its pharmacokinetics and pharmacodynamics. We employed spectroscopic approaches, including circular dichroism spectrometry and fluorescence spectroscopy, to investigate the binding of saquinavir to BSA.

View Article and Find Full Text PDF

Antiviral Agents: Structural Basis of Action and Rational Design.

Subcell Biochem

December 2024

Department of Biomedical Sciences, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain.

During the last forty years, significant progress has been made in the development of novel antiviral drugs, mainly crystallizing in the establishment of potent antiretroviral therapies and the approval of drugs eradicating hepatitis C virus infection. Although major targets of antiviral intervention involve intracellular processes required for the synthesis of viral proteins and nucleic acids, a number of inhibitors blocking virus assembly, budding, maturation, entry, or uncoating act on virions or viral capsids. In this review, we focus on the drug discovery process while presenting the currently used methodologies to identify novel antiviral drugs by means of computer-based approaches.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!